Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Okayama University Research: Successful Test of Retinal Prosthesis Implanted in Rats
  • USA - English


News provided by

Okayama University

Apr 20, 2017, 00:00 ET

Share this article

Share toX

Share this article

Share toX

The main component of Okayama University-type retinal prosthesis (OURePTM) is a photoelectric dye molecule.
The main component of Okayama University-type retinal prosthesis (OURePTM) is a photoelectric dye molecule.

Okayama, Japan (PRWEB UK) 20 April 2017 -- Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 20 April 2017

Researchers at Okayama University report in the Journal of Artificial Organs the promising performance of a retinal prosthesis material that can convert external light stimuli into electric potentials that are picked up by neurons. The results are an important step towards curing certain hereditary eye diseases.

A first-in-human clinical trial for OURePTM at Okayama University Hospital ... will be planned in consultation with [Japan’s] Pharmaceuticals and Medical Devices Agency.

Post this

Retinitis pigmentosa is a hereditary retinal disease, causing blindness due to dead photoreceptor cells but with other retinal neurons being alive. A potential remedy for patients diagnosed with this disease are prostheses replacing the non-functioning photoreceptor cells with artificial sensors, and making use of the functioning of the remaining, living neurons. Now, a team of researchers from Okayama University led by Toshihiko Matsuo & Tetsuya Uchida has quantitatively tested the response of a promising type of prosthesis, when implanted in rats, to external light flashes — a crucial step in the further development of retinal prostheses.

The prosthesis tested by the researchers was developed earlier at Okayama University, and is known as Okayama University-type retinal prosthesis (OURePTM). The main component of OURePTM is a photoelectric dye: an organic molecule capable of converting light into electric potentials. Uchida and colleagues attached the dye molecules to a thin film of polyethylene — a safe and stable biocompatible material — and implanted the dye-coupled film (of size 1 mm x 5 mm) subretinally in the eyes of 10 male rats 6 weeks old. Cranial electrodes for registering potentials were attached 2–3 weeks later. The researchers also implanted plain, polyethylene films in 10 other rats for comparison purposes.

The scientists tested the response of the implanted OURePTM sensors to flashing white light-emitting diodes (LEDs) placed on the surface of the rats’ corneas (the transparent front parts of the eyes) for different background-light conditions. The experiments were done with the rats anesthetized, and after appropriate periods of adaptation to dark or light conditions. Comparisons between results obtained with dye-coupled films and plain polyethylene films showed that the former led to visually evoked potentials — confirming the potential of OURePTM as a retinal prosthesis for treating diseases like retinitis pigmentosa.

The use of OURePTM poses no toxicity issues and, because of the high density of the dye molecules on the polyethylene film, offers a high spatial resolution. Regarding tests on human eyes, Matsuo and colleagues point out that “a first-in-human clinical trial for OURePTM at Okayama University Hospital ... will be planned in consultation with [Japan’s] Pharmaceuticals and Medical Devices Agency.”

Background
OURePTM
Okayama University-type retinal prosthesis (OURePTM), developed at Okayama University, is a material that mimics the function of photoreceptor cells present in mammalian eyes: phototransduction, the conversion of light into neuron signals triggering biological processes. The main component of OURePTM are 2-[2-[4-(dibutylamino)phenyl]ethenyl]-3-carboxymethylbenzothiazolium bromide molecules, photoelectric dye molecules that can convert light into electric potentials. These molecules are attached to the surface of a thin polyethylene film; the resulting dye-coupled OURePTM film can be used as an implant replacing non-functioning photoreceptor cells. OURePTM is a particularly promising prosthesis in situations — such as for the disease retinitis pigmentosa — where other retinal neuron cells, sending neuron signals to the brain, are still active.

Competing strategies
Other approaches for remedying dead photoreceptor cells rely on the use of a digital video camera integrated into glasses worn by the patient. The video images are converted to electrical signals transmitted to a receiver implanted in the patient’s body, after which electric currents are sent out of an array of electrodes implanted around the patient’s retina. Challenges associated with this type of approach, as e.g. implemented in the Argus IITM Retinal Prosthesis System (Second Sight, Inc.), include the miniaturization of the components, their biocompatibility, achieving high spatial resolution, and the need for an external power source. As demonstrated by the team led by Toshihiko Matsuo, the use of OURePTM overcomes these issues..

Reference
Alamusi, Toshihiko Matsuo, Osamu Hosoya & Tetsuya Uchida. Visual evoked potential in RCS rats with Okayama University-type retinal prosthesis (OURePTM) implantation. Journal of Artificial Organs, 08 February, 2017.
DOI:10.1007/s10047-016-0943-4
https://link.springer.com/article/10.1007%2Fs10047-016-0943-4

Further information
Okayama University
Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

Okayama University Medical Research Updates(OU-MRU)
http://www.okayama-u.ac.jp/user/res-ehp/html/impact.html

Vol.38:Bioengineered tooth restoration in a large mammal
http://www.okayama-u.ac.jp/eng/research_highlights/index_id49.html

Hiromi Tokiwa, Okayama University, +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.